0VQ0.F PURETECH HLTH ADRS 10
- Market cap
- EUR 346M
- P/E
- -
- P/B
- 0.98x
- ROE
- -35.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0VQ0.F undervalued?
Graham numberThe Graham number of PURETECH HLTH ADRS 10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PURETECH HLTH ADRS 10 fundamental analysis
No fundamental analysis for PURETECH HLTH ADRS 10 yet.
PURETECH HLTH ADRS 10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PURETECH HLTH ADRS 10
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnano…
Full company profilePURETECH HLTH ADRS 10 financial statements
PURETECH HLTH ADRS 10 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 9.98M | 2.09M | 750K | 4.32M | 4.66M |
| Operating Income | -150M | -198M | -146M | -136M | -98.5M |
| EBITDA | - | -79.9M | -17.7M | 37.4M | -61.8M |
| Net Income | -60.6M | -50.4M | -65.7M | 53.5M | -110M |
| EPS | -0.21 | -0.18 | -0.24 | 0.22 | -0.45 |
| Balance Sheet | |||||
| Total Assets | 946M | 703M | 694M | 603M | 535M |
| Total Liabilities | 362M | 155M | 236M | 195M | 229M |
| Shareholders' Equity | 594M | 542M | 464M | 415M | 312M |
| Cash & Short-term Investments | 466M | 150M | 191M | 281M | 252M |
| Cash Flow | |||||
| Operating Cash Flow | -158M | -179M | -106M | -134M | -85.1M |
| Capital Expenditure | 5.66M | 2.18M | 245K | 11.0K | 6.00K |
| Free Cash Flow | -164M | -181M | -106M | -134M | -85.1M |
| Ratios | |||||
| ROE | -10.2% | -9.3% | -14.2% | 12.9% | -35.2% |
| ROA | -6.4% | -7.2% | -9.5% | 8.9% | -20.5% |
| Net Profit Margin | -606.9% | -2,409.3% | -8,759.6% | 1,240.1% | -2,355.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PURETECH HLTH ADRS 10 dividends
PURETECH HLTH ADRS 10 has not paid dividends in the last 5 fiscal years.
Who owns PURETECH HLTH ADRS 10
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 24.3M
- Free float 16.2M
PURETECH HLTH ADRS 10 company profile
- Company name
- PURETECH HLTH ADRS 10
- Ticker
- 0VQ0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
- Fiscal year end
- December
- Address
- 6 Tide Street, Boston, MA, United States, 02210
- Phone
- 617 482 2333
- Website
- puretechhealth.com
About PURETECH HLTH ADRS 10
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
PURETECH HLTH ADRS 10 management
10- Mr. Robert Lyne J.D., L.L.B.CEO & Director · born 1983
- Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Non-Executive Director · born 1949
- Dr. Eric Elenko Ph.D.Co-founder · born 1973
- Dr. David R. Elmaleh Ph.D.Co-Founder & Senior Advisor · born 1948
- Ms. Lauren A. White M.B.A.Chief Financial Officer · born 1979
- Mr. Michael Inbar CPA, M.B.A.Chief Accounting Officer
- Ms. Allison Mead TalbotSenior VP of Communications & Head of Investor Relations
- Ms. Aleksandra Filipovic M.D., Ph.D.Head of Oncology
- Ms. Joy Bauer M.S., RDNChief Nutrition Officer
- Dr. Camilla S. Graham M.D., M.P.H.Senior Vice President of Medical Affairs